An interventional study of resuscitative endovascular occlusion of the aorta (REBOA) and Advanced Cardiac Life Support (ACLS) in Cardiac Arrest, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Treatment
This study will test if a sustained Return of Spontaneous Circulation (ROSC) in patients with cardiac arrest is more frequent when patients receive advanced cardiac life support (ACLS) alone or when they receive ACLS plus a balloon occlusion of the thoracic aorta.
Patients with in-hospital cardiac arrest (IHCA) outside the operating room, the coronary angiography suite and the intensive care unit (ICU) will be attended to by the hospitals resuscitation team and provided with advanced cardiac life support (ACLS) as per usual practice.
A research team will be deployed simultaneously and, when patients meet inclusion criteria, will randomize patients to ACLS alone or to ACLS plus balloon occlusion of the descending thoracic aorta by means of a resuscitative endovascular occlusion of the aorta (REBOA) catheter.
965 studies on the registry are indexed under Heart Arrest; 226 are open to participants now.
This study's planned enrollment of 98 is close to the median of 100 across 557 interventional studies indexed under Heart Arrest.
Browse Heart Arrest studies →Insel Gruppe AG, University Hospital Bern is the lead sponsor of 724 studies on the registry; 177 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Advanced Cardiac Life Support (ACLS) as per the hospitals standard protocol, including advanced interventions such as extended cardio-pulmonary resuscitation (eCPR).
Other: Advanced Cardiac Life Support (ACLS)
Advanced Cardiac Life Support (ACLS) as per the hospitals standard protocol, including advanced interventions such as eCPR plus resuscitative balloon occlusion of the descending thoracic aorta (REBOA).
Device: resuscitative endovascular occlusion of the aorta (REBOA) · Other: Advanced Cardiac Life Support (ACLS)
Insertion of a balloon catheter through the common femoral artery, retrograde advancement of the catheter into the descending thoracic aorta, ballon occlusion of the aorta
Advanced Cardiac Life Support (ACLS) as per American Heart Association (AHA) or European Resuscitation Council (ERC) standards
Sustained ROSC
Any return of spontaneous circulation lasting longer then 20 minutes
Time frame: Up to 1 hour after study inclusion
Survival to hospital discharge
dead or alive
Time frame: at hospital discharge, up to 90 days after study inclusion
Survival to six month
dead or alive
Time frame: 6 month after study inclusion
neurologic outcome at the time of 30 days
measured by means of modified ranking scale
Time frame: Day 30 after study inclusion
neurologic outcome at the time of six month
measured by means of modified ranking scale
Time frame: 6 month after study inclusion
ICU-free days before hospital discharge
Time frame: at hospital discharge, up to 90 days after study inclusion
ICU-free days at 30 days
Time frame: 30 days after study inclusion
non-invasive cerebral oxygenation during resuscitation
Exploratory, measured in %
Time frame: Continuously assessed during ongoing resuscitation, up to 1 hour after study inclusion
cause of death
exploratory, written description
Time frame: at six month
Troponin T trajectory
exploratory
Time frame: at inclusion, 30 minutes after inclusion and once up to day 3
Neuron-Specific Enolase (NSE) trajectory
exploratory
Time frame: at inclusion, 30 minutes after inclusion and once up to day 3
Plan to share: Yes — All IBD (including data dictionaries) will be shared upon reasonable request with researcher eligible health data under Swiss legislation. Eligibility will be determined by Cantonal Ethics Committee of Bern. This determination will require submission of a research plan to the ethics committee. Data will be provided as electronic files in STATA file format as exported from the RedCap study database. The trials study protocol is available on the trial website at http://cpreboa.org. The statistical analysis protocol will become available on the trial website an in the Zenodo registry before inclusion of the last patient into the trial.
Supporting information: Study protocol, Sap, Icf, Analytic code
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern